Pregabalin Capsule
Product Images NDC 72162-1547

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 72162-1547). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Label (Lbl721621547)

Label (Lbl721621547)
This is a description of Pregabalin capsules containing 225mg of USP. The capsules should be stored at a temperature between 20°C to 25°C (68°F to 77°F) and can be permitted to a range of 15°C to 30°C (59°F to 86°F). The capsules are to be kept away from children, and the manufacturer is Bryant Ranch Prepack, Inc. The manufacturer of the drug is ScieGen Pharmaceuticals, Inc. This drug is a prescription drug.*
FDA Label Image

Figure 1 (Pregabalin Fig01)

Figure 1 (Pregabalin Fig01)
FDA Label Image

Figure 2 (Pregabalin Fig02)

Figure 2 (Pregabalin Fig02)
This appears to be a chart showing the percentage improvement in pain from a baseline for patients taking Pregabalin 160 mg for three days. The chart lists numbers for "2w," "220," "23," "20," "280," "2," "20," and "23w." It is unclear what these numbers represent.*
FDA Label Image

Figure 3 (Pregabalin Fig03)

Figure 3 (Pregabalin Fig03)
The text provides information on various medications and the percentage of patients improved with them. It also shows the dosage of the medications. However, the text appears to be incomplete and does not provide clear context or unit of measurement for the percentage values. Therefore, it is not possible to generate a useful description for this text.*
FDA Label Image

Figure 4 (Pregabalin Fig04)

Figure 4 (Pregabalin Fig04)
FDA Label Image

Figure 5 (Pregabalin Fig05)

Figure 5 (Pregabalin Fig05)
This appears to be a table or chart showing the dosages and frequencies of medications (Fregabalin, Pregataiin, and Placebo) and the percentage of patients who improved, as well as the percentage of improvement in pain from baseline. However, the text has numerous inaccuracies and missing information, making it difficult to provide a more detailed description.*
FDA Label Image

Figure 6 (Pregabalin Fig06)

Figure 6 (Pregabalin Fig06)
The text appears to be a table showing the names of some studies and dosages of a drug tested as well as some statistical information, however, without any context or further explanation, it is not possible to provide a meaningful description.*
FDA Label Image

Figure 7 (Pregabalin Fig07)

Figure 7 (Pregabalin Fig07)
FDA Label Image

Figure 9 (Pregabalin Fig08)

Figure 9 (Pregabalin Fig08)
The text shows a graph representing the percent of patients improved in pain from baseline after taking Pregabalin at different doses, compared to a placebo. The graph only provides information on the Pregabalin 300mg daily dose and the Pregabalin 450mg daily dose. The X-axis shows the range of percent improvement from baseline, while the Y-axis represents the different treatments. No further information is available.*
FDA Label Image

Figure 10 (Pregabalin Fig09)

Figure 10 (Pregabalin Fig09)
This appears to be a table displaying estimated percentages of subjects without LTR (Likely Treatment Response) for different time periods. The rows show percentages ranging from 0 to 100, in increments of 10, while the columns represent the day count. The first column appears to show treatment names: "Progabain" and "Placebo". Overall, it seems to be a study related to treatment response rates in a clinical trial.*
FDA Label Image

Figure 11 (Pregabalin Fig10)

Figure 11 (Pregabalin Fig10)
This is a table that shows the percentage of subjects improved in a study, with the categories of improvement listed on the left-hand side. The brands "Pregetalin" and "Placeso" are mentioned, but it is unclear what they refer to.*
FDA Label Image

Figure 12 (Pregabalin Fig11)

Figure 12 (Pregabalin Fig11)
The text seems to be a table or chart showing the percentage of subjects improved from baseline to week 16. The data is divided into two columns for Pregabalin and Placebo. The percentage of improvement ranges from 100 to 280 and is measured in increments of 10. Perhaps it is a study or clinical trial evaluating the effectiveness of pregabalin compared to a placebo in improving certain conditions.*
FDA Label Image

Cockcroft And Gault Equation (Pregabalin Formula)

Cockcroft And Gault Equation (Pregabalin Formula)
This text appears to be a formula for calculating CLCT (creatinine clearance), which is a measure of how well the kidneys are functioning. The formula involves multiplying the difference between 140 and the patient's age (in years) by their weight (in kilograms), then multiplying the result by 0.85 for female patients. The final step is to multiply the product by their serum creatinine level (in mg/dL) divided by 72.*
FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical Structure (Pregabalin Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.